Mutant KRAS G12V-specific TCR tranduced autologous T cell therapy (Changhai Hospital of Shanghai)

N/A

Report date: 2022/12/27 09:23:00

Base Information

Drug NameMutant KRAS G12V-specific TCR tranduced autologous T cell therapy (Changhai Hospital of Shanghai)
Drug Alias NameMutant KRAS G12V-specific TCR tranduced autologous T cells
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionKRAS G12V modulators
TargetsKRAS G12V
Therapy Area/IndicationsPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesChanghai Hospital of Navy Medical University
China Registration ClassN/A

Develop Information

Active CompaniesChanghai Hospital of Navy Medical University
Inactive CompaniesN/A
Active IndicationsPancreatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A